Biohaven Ltd. Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised
Biohaven Ltd. (BHVN) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised of $3.93 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans · last filed 2026-08-10
- Biohaven Ltd. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2026-06-30 was $3.80M, a 252.46% increase year-over-year.
- Biohaven Ltd. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2026-03-31 was $132.00K, a 64.23% decline year-over-year.
- Biohaven Ltd. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-06-30 was $1.08M.
- Biohaven Ltd. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-03-31 was $369.00K.
- Biohaven Ltd. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2025 was $1.83M, a 84.06% decline from fiscal 2024.
- Biohaven Ltd. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2024 was $11.50M, a 144.96% increase from fiscal 2023.
- Biohaven Ltd. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2023 was $4.70M, a 941.02% increase from fiscal 2022.
- Biohaven Ltd. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2022 was $451.00K, a 14.18% increase from fiscal 2021.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 6 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 12 month |
|---|---|---|---|
| 2026-06-30 | $3.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $3.93M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $132.00K 10-Q · filed 2026-05-04 | ||
| 2025-12-31 | $1.83M 10-K · filed 2026-03-02 | ||
| 2025-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.45M 10-Q · filed 2026-08-10 | |
| 2025-03-31 | $369.00K 10-Q · filed 2026-05-04 | ||
| 2024-12-31 | $11.50M 10-K · filed 2026-03-02 | ||
| 2023-12-31 | $4.70M 10-K · filed 2026-03-02 | ||
| 2022-12-31 | $451.00K 10-K · filed 2025-03-03 | ||
| 2021-12-31 | $395.00K 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |